Develops and markets Lumega-Z, a medical food for macular pigment replenishment. Now — the numbers.
This is an established company with proven profits.
Average growth of 92% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $6.4M would still be left in the vault — a solid cushion for hard times.
The market pays 26.4× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 100% below today's price.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 92% a year on average.
There is $6.4M in the vault; even if every debt were paid off, $6.4M would remain.
The stock trades 100% above the average analyst price target.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.